请输入关键字
请输入关键字
订购
*国家
中国
美国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hCD16A mice
Strain Name C57BL/6-Fcgr4tm2(FCGR3A)/Bcgen  Common Name  B-hCD16A mice
Background C57BL/6 Catalog number  111173
Related Genes 
FCGR3A (Fc fragment of IgG receptor IIIa), CD16A

Gene description

CD16 is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophils, monocytes, and macrophages, and has been identified as Fc receptors FcγRIIIa (CD16a, Low affinity immunoglobulin gamma Fc region receptor III-A. FCGR3A, gene ID 2214) and FcγRIIIb (CD16b), which participate in signal transduction. The most well-researched membrane receptor implicated in triggering lysis by NK cells, CD16 is a molecule of the immunoglobulin superfamily (IgSF) involved in antibody-dependent cellular cytotoxicity (ADCC). It can be used to isolate populations of specific immune cells through fluorescent-activated cell sorting (FACS) or magnetic-activated cell sorting, using antibodies directed towards CD16. While FcγRIIIa is expressed on mast cells, macrophages, and natural killer cells as a transmembrane receptor, FcγRIIIb is only expressed on neutrophils. In addition, FcγRIIIb is the only Fc receptor anchored to the cell membrane by a glycosyl-phosphatidylinositol (GPI) linker, and also plays a significant role in triggering calcium mobilization and neutrophil degranulation. FcγRIIIa and FcγRIIIb together are able to activate degranulation, phagocytosis, and oxidative burst, which allows neutrophils to clear opsonized pathogens. With its expression on neutrophils, CD16 represents a possible target in cancer immunotherapy. Margetuximab, an Fc-optimized monoclonal antibody that recognizes the human epidermal growth factor receptor 2 (HER2) expressed on tumor cells in breast, bladder, and other solid tumor cancers, targets CD16A in preference to CD16B. In addition, CD16 could play a role in antibody-targeting cancer therapies. FcγRIV, a murine homologue of CD16A has been shown to be involved in antibody-mediated depletion of tumor-infiltrating regulatory T cells in monoclonal antibody mediated immunotherapy. Bispecific antibody fragments, such as anti-CD19/CD16, allow the targeting of immunotherapeutic drugs to the cancer cell. Anti-CD19/CD16 diabodies have been shown to enhance the natural killer cell response to B-cell lymphomas. Furthermore, targeting extrinsic factors such as FasL or TRAIL to the tumor cell surface triggers death receptors, inducing apoptosis by both autocrine and paracrine processes.

Protein expression analysis in NK cells


from clipboard


Strain specific CD16A expression analysis in wild-type C57BL/6 mice and heterozygous B-hCD16A mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice(+/+)  and heterozygous B-hCD16A mice(H/+). Mouse Fcgr4 was not detectable in NK cells of wild-type C57BL/6 mice and heterozygous B-hCD16A mice, which was consistent with the expected results. Human CD16A was exclusively detectable in NK cells of heterozygous B-hCD16A mice.

Protein expression analysis in granulocytes

from clipboard


Strain specific CD16A expression analysis in wild-type C57BL/6 mice and heterozygous B-hCD16A mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice(+/+)  and heterozygous B-hCD16A mice(H/+). Mouse Fcgr4 was detectable in granulocytes of wild-type C57BL/6 mice and heterozygous B-hCD16A mice. Human CD16A was not exclusively detectable in granulocytes of heterozygous B-hCD16A mice, which was consistent with the expected results.

Protein expression analysis in macrophages

from clipboard


Strain specific CD16A expression analysis in wild-type C57BL/6 mice and heterozygous B-hCD16A mice by flow cytometry. Peritoneal exudative macrophages(PEMs) were collected from wild-type C57BL/6 mice(+/+)  and heterozygous B-hCD16A mice(H/+). Mouse Fcgr4 was detectable both in PEMs of wild-type C57BL/6 mice and heterozygous B-hCD16A mice. Human CD16A was exclusively detectable in PEMs of heterozygous B-hCD16A mice.